ABSTRACT
Antecedentes: El autoinjerto de válvula pulmonar (VP) u operación de Ross (OpR) tiene excelentes resultados a largo plazo. Es superior a otros tipos de reemplazo valvular en jóvenes adultos, aunque no el estándar de primera línea. Un tiempo quirúrgico prolongado o alta morbimortalidad son importantes preocupaciones. Objetivos: Establecer la morbimortalidad asociada a la OpR por un período >10 años, considerando el tiempo quirúrgico, tasa de reoperación y supervivencia global (SG). Métodos: Cohorte prospectiva (1996-2012), en seguimiento hasta agosto-2023. La SG fue estimada desde la OpR hasta la última consulta o deceso. Mediante regresión de Cox (Hazard Ratio, HR) se estimaron factores asociados a la SG. Resultados: La serie consta de 161 pacientes: 118 de etiología congénita (73.3%), 17 infecciosa (10.6%), 26 reumática (16.1%). La lesión fue estenótica en 79 (49.1%), insuficiencia en 40 (24.8%), mixta en 42 (26.1%). La OpR fue urgente en 11 (6.8%). The median time of ECC and the operation was 149 y 232 minutos, respectivamente. Veintisiete pacientes requirieron reoperación (16.8%). Con una mediana de 19.7 años (17.2-22.2), 23 pacientes fallecieron (14.3%): 1/23 asociado a OpR, 17/23 por causa cardiovascular y 5/23 por causas no cardiovasculares. La lesión mixta se asoció a mayor mortalidad (HR 3.07; IC 95% 1.11-8.47; p=.029). Conclusiones: La OpR es un procedimiento con baja morbimortalidad. La lesión mixta es un factor de riesgo independiente de mayor mortalidad. Sin embargo, la mediana de tiempo de CEC y quirúrgico es prolongado frente a otras técnicas de reemplazo valvular.
Background: Pulmonary valve (PV) autograftor reoperation or Ross surgery (RS), presents excellent long-term results. It is superior to other types of PV replacement in young adults, although it is not the first-line gold standard. A longer operative time or high morbidity and mortality rates are important concerns. Aim: To establish the morbidity and mortality associated with RS for >10 years, considering operative time, reoperation rate and overall survival (OS). Methods: Prospective cohort (1996-2012), with a follow-up until August/2023. The OS was estimated from RS to the last consultation/death. Factors associated to OS were estimated using Cox regression (Hazard Ratio, HR) Results: 161 patients were included: the etiology was congenital (118, 73%), infectious (17, 10.6%), and rheumatic (26,16.1%). The lesion was stenotic in 79 (49.1%), heart failure in 40 (24.8%), mixed in 42 (26.1%). RS was urgent in 11 (6.8%). Extracorporeal circulation (ECC) and operative times were 149 and 232 minutes, respectively. Twenty-seven patients required reoperation (16.8%). With a median follow up of 19.7 years (17.2-22.2), 23 patients died (14.3%): 1/23 associated with RS, 17/23 due to cardiovascular causes, and 5/23 due to non-cardiovascular causes. Mixed injury was associated with higher mortality (HR 3.07; 95% CI 1.11-8.47; p=.029). Conclusions: RS is a procedure with low morbidity and mortality. Mixed injury is an independent risk factor for increased mortality. However, the median ECC and operative times were higher compared to other valvular replacement techniques.
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Pulmonary Valve/surgery , Pulmonary Valve Insufficiency , Thoracic Surgery/statistics & numerical data , Postoperative Complications , Reoperation/statistics & numerical data , Thoracic Surgery/methods , Transplantation, Autologous/statistics & numerical data , Survival Analysis , Chile , Prospective Studies , Follow-Up StudiesABSTRACT
Objectives: To evaluate the feasibility and preliminary clinical results of transcatheter pulmonary valve replacement (TPVR) with the domestically-produced balloon-expandable Prizvalve system. Methods: This is a prospective single-center observational study. Patients with postoperative right ventricular outflow tract (RVOT) dysfunction, who were admitted to West China Hospital of Sichuan University from September 2021 to March 2023 and deemed anatomically suitable for TPVR with balloon-expandable valve, were included. Clinical, imaging, procedural and follow-up data were analyzed. The immediate procedural results were evaluated by clinical implant success rate, which is defined as successful valve implantation with echocardiography-assessed pulmonary regurgitation<moderate and peak trans-pulmonary pressure gradient<40 mmHg (1 mmHg=0.133 kPa). Results: A total of 5 patients were included, with 4 males, aged 14 to 37 years. The initial diagnosis included Tetralogy of Fallot (2 cases), truncus arteriosus (1 case), pulmonary atresia (1 case) and subaortic stenosis (1 case, prior Ross procedure). Four patients underwent RVOT reconstruction with homograft or artificial conduit, and one patient was treated with trans-annular patch technique. The indications of TPVR included RVOT obstruction and regurgitation (3 cases), isolated obstruction (1 case), and isolated regurgitation (1 case). Of the 4 patients with varying severity of ROVT obstruction, the average preprocedural peak jet velocity of RVOT was 3.5 m/s, and the average peak pressure gradient was 50.0 mmHg. Except for one patient, who had previously been implanted with a covered Cheatham-Platinum (CP) stent due to severe stenosis of the main pulmonary artery, other patients underwent pre-stenting with a covered CP stent before TPVR. Clinical implant success was achieved in all of the 5 patients, and there was no serious periprocedural complications. The average trans-pulmonary peak jet velocity and peak pressure gradient derived from postprocedural echocardiography was 2.3 m/s and 21.2 mmHg, respectively. All patients experienced significant symptom relief after the procedure. All patients completed 3-month follow-up, and 4 completed 6-month follow-up. There was no case of infectious endocarditis during follow-up. All patients were graded as NYHA functional class one at the latest follow-up. Conclusions: TPVR using the domestically-produced balloon-expandable Prizvalve system is safe and feasible for the treatment of patients with post-surgical RVOT dysfunction and suitable landing-zone anatomy. The safety, effectiveness, and long-term valve durability of the Prizvalve system deserve further research.
Subject(s)
Male , Humans , Pulmonary Valve/surgery , Heart Valve Prosthesis/adverse effects , Heart Valve Prosthesis Implantation , Constriction, Pathologic/surgery , Prospective Studies , Ventricular Outflow Obstruction/surgery , Treatment Outcome , Cardiac Catheterization/methods , Transcatheter Aortic Valve ReplacementABSTRACT
Objectives: To evaluate the feasibility and preliminary clinical results of transcatheter pulmonary valve replacement (TPVR) with the domestically-produced balloon-expandable Prizvalve system. Methods: This is a prospective single-center observational study. Patients with postoperative right ventricular outflow tract (RVOT) dysfunction, who were admitted to West China Hospital of Sichuan University from September 2021 to March 2023 and deemed anatomically suitable for TPVR with balloon-expandable valve, were included. Clinical, imaging, procedural and follow-up data were analyzed. The immediate procedural results were evaluated by clinical implant success rate, which is defined as successful valve implantation with echocardiography-assessed pulmonary regurgitation<moderate and peak trans-pulmonary pressure gradient<40 mmHg (1 mmHg=0.133 kPa). Results: A total of 5 patients were included, with 4 males, aged 14 to 37 years. The initial diagnosis included Tetralogy of Fallot (2 cases), truncus arteriosus (1 case), pulmonary atresia (1 case) and subaortic stenosis (1 case, prior Ross procedure). Four patients underwent RVOT reconstruction with homograft or artificial conduit, and one patient was treated with trans-annular patch technique. The indications of TPVR included RVOT obstruction and regurgitation (3 cases), isolated obstruction (1 case), and isolated regurgitation (1 case). Of the 4 patients with varying severity of ROVT obstruction, the average preprocedural peak jet velocity of RVOT was 3.5 m/s, and the average peak pressure gradient was 50.0 mmHg. Except for one patient, who had previously been implanted with a covered Cheatham-Platinum (CP) stent due to severe stenosis of the main pulmonary artery, other patients underwent pre-stenting with a covered CP stent before TPVR. Clinical implant success was achieved in all of the 5 patients, and there was no serious periprocedural complications. The average trans-pulmonary peak jet velocity and peak pressure gradient derived from postprocedural echocardiography was 2.3 m/s and 21.2 mmHg, respectively. All patients experienced significant symptom relief after the procedure. All patients completed 3-month follow-up, and 4 completed 6-month follow-up. There was no case of infectious endocarditis during follow-up. All patients were graded as NYHA functional class one at the latest follow-up. Conclusions: TPVR using the domestically-produced balloon-expandable Prizvalve system is safe and feasible for the treatment of patients with post-surgical RVOT dysfunction and suitable landing-zone anatomy. The safety, effectiveness, and long-term valve durability of the Prizvalve system deserve further research.
Subject(s)
Male , Humans , Pulmonary Valve/surgery , Heart Valve Prosthesis/adverse effects , Heart Valve Prosthesis Implantation , Constriction, Pathologic/surgery , Prospective Studies , Ventricular Outflow Obstruction/surgery , Treatment Outcome , Cardiac Catheterization/methods , Transcatheter Aortic Valve ReplacementABSTRACT
Objective: To explore the efficacy and safety of transcatheter pulmonary valve perforation in the treatment of neonatal pulmonary atresia with intact ventricular septum (PA-IVS). Methods: The clinical data on surgical treatment and follow-up in 16 patients with PA-IVS who underwent transcatheter pulmonary valve perforation in Women and Children's Hospital, Qingdao University from October 2018 to October 2021 were analyzed retrospectively. The right ventricular systolic pressure and percutaneous oxygen saturation (SpO2) were compared before and after operation. In addition, the SpO2 and echocardiographic data at preoperative and the last follow-up were compared. Comparisons between groups were performed using paired-samples t test. Results: Among the 16 patients (10 males and 6 females) with the age at operation of 19 (14, 26) days, 12 cases underwent transcatheter pulmonary valve perforation successfully, 2 cases were transferred to surgery department for open-heart pulmonary valvulotomy, and the remaining 2 cases were transmitted to surgery department for transthoracic pulmonary valve perforation. The age at operation of the 12 patients who underwent transcatheter pulmonary valve perforation was 18 (14, 27) days, and the weight was (3.6±0.4) kg. The immediate postoperative right ventricular systolic pressure decreased significantly ((57±16) vs. (95±19) mmHg (1 mmHg=0.133 kPa), t=7.49, P<0.001), and the postoperative SpO2 was improved effectively (0.90±0.48 vs.0.75±0.09, t=-5.61, P<0.001). The follow-up time was 22 (7, 33) months for 12 patients who underwent transcatheter pulmonary valve perforation successfully. At the last follow-up, the ratio of right to left ventricular transverse diameter was significantly higher than that before operative (0.55±0.05 vs. 0.45±0.05, t=-3.27,P=0.007). Furthermore, the Z-scores of pulmonary valvular diameter (-0.78±0.23 vs. -1.73±0.56, t=-8.52, P<0.001) and the tricuspid valvular diameter (-0.52±0.12 vs. -1.46±0.38, t=-10.40, P<0.001) were all significantly higher than preoperative data. At last, all the patients achieved biventricular circulation without death or major complications. Conclusion: Transcatheter pulmonary valve perforation is a safe and effective therapy for neonatal PA-IVS, and its curative effect has been confirmed by the medium follow-up data.
Subject(s)
Child , Male , Infant, Newborn , Humans , Female , Pulmonary Valve/surgery , Retrospective Studies , Pulmonary Atresia/surgery , Heart Defects, CongenitalABSTRACT
Abstract Introduction: Reconstruction of right ventricular outflow tract during primary repair of tetralogy of Fallot often requires the placement of a transannular patch which results in pulmonary regurgitation (PR). We compared the short-term outcomes of bicuspid polytetrafluoroethylene membrane valve versus transannular pericardial patch reconstruction of the right ventricular outflow tract. Methods: Thirty consecutive patients undergoing primary repair of tetralogy of Fallot were randomly allocated to two groups - polytetrafluoroethylene valve (PTFEV) group (n=15) and transannular pericardial patch (TAP) group (n=15). The two groups had similar preoperative demographic characteristics. We compared the short-term clinical and echocardiographic outcomes between these groups. The transthoracic echocardiographic follow-up was performed at one week, one month and six months after surgery. Results: The PTFEV group had significantly lower central venous pressure in the immediate postoperative period compared to the TAP group (7.60±2.06 vs. 10.13±1.73, P=0.002). Extubation time was significantly shorter in the PTFEV group compared to the TAP group (12.93±7.55 hrs vs. 22.23±15.11 hrs, P=0.04). PR in the PTFEV group was absent in five patients at 24 hours post-surgery. At the study endpoint, PR was absent in six, trivial in one and mild in eight patients in the PTFEV group compared to TAP group, where all 15 patients had severe PR. Conclusion: The bicuspid polytetrafluoroethylene membrane valves significantly decrease the central venous pressure in the immediate postoperative period, facilitate early extubation and, thus, prevent ventilator-related comorbidities. They achieve a high degree of pulmonary competence and do not increase the right ventricular outflow tract gradient in short-term follow-up.
Subject(s)
Humans , Infant , Pulmonary Valve/surgery , Pulmonary Valve Insufficiency , Tetralogy of Fallot/surgery , Cardiac Surgical Procedures , Polytetrafluoroethylene , Treatment OutcomeSubject(s)
Humans , Adult , Pulmonary Valve/surgery , Pulmonary Valve/pathology , Endocarditis/microbiology , Endocarditis/diagnostic imaging , Heart Ventricles/physiopathology , Patient Discharge , Candida albicans , Echocardiography/methods , Comorbidity , Balloon Valvuloplasty/methods , Computed Tomography Angiography/methods , Heart Valve Diseases/pathology , Hospitalization , Infections , Infections/blood , Intensive Care UnitsABSTRACT
Resumen Los pacientes con cardiopatías congénitas que afectan la continuidad del ventrículo derecho con la arteria pulmonar deben someterse con frecuencia a intervenciones debido a la limitada vida útil de los conductos quirúrgicos, lo que lleva al desarrollo de disfunción ventricular derecha por cambios en la geometría ventricular y predisposición a arritmias letales, con el consiguiente riesgo de reintervenciones. El implante valvular percutáneo pulmonar es una nueva alternativa terapéutica, menos invasiva en comparación con la quirúrgica, para pacientes seleccionados. Se realiza una revisión de las publicaciones médicas actuales disponibles y se describe la experiencia inicial del implante valvular pulmonar percutáneo en un centro colombiano de alta complejidad para el tratamiento de enfermedades cardiovasculares, en dos pacientes con disfunción del homoinjerto aórtico en posición pulmonar con doble lesión valvular, en los cuales el implante valvular pulmonar percutáneo fue una conducta exitosa. Se eligió a pacientes con cardiopatías congénitas, conductos quirúrgicos disfuncionales con estenosis o insuficiencia pulmonar significativa, y disfunción y dilatación ventricular derechas. Se empleó la técnica regular para el implante de la válvula pulmonar Melody, sin documentarse complicaciones durante el procedimiento ni al año de seguimiento. El implante percutáneo de la válvula pulmonar es un gran avance en el tratamiento de pacientes con cardiopatías congénitas, con resultados favorables a corto y mediano plazos, lo cual hace posible la restauración de la función ventricular con riesgo mínimo, frente al reemplazo quirúrgico en pacientes seleccionados.
Abstract Patients with congenital heart disease that involves reconstruction of the right ventricular outflow tract must frequently undergo interventions derived from the limited useful life of the surgical canals, which leads to the development of right ventricular dysfunction due to changes in the ventricular geometry and predisposition to lethal arrhythmias, with the consequent risk of reinterventions. The percutaneous pulmonary valvular implant is a new therapeutic alternative, less invasive, compared to surgery, for selected patients. A review of the available literature is made and the initial experience of percutaneous pulmonary valve implantation in a Colombian center of high complexity for the treatment of cardiovascular diseases is described, in two patients with aortic homograft dysfunction in a pulmonary position with double valvular lesion, in which the percutaneous pulmonary valve implant was a successful strategy. Patients with congenital heart disease were chosen, with dysfunctional surgical conduits with stenosis or significant pulmonary insufficiency, with dysfunction and right ventricular dilatation. The standard technique for the implantation of the Melody pulmonary valve was used, without complications during the procedure or one year of follow-up. Percutaneous implantation of the pulmonary valve is a great advance in the management of patients with congenital heart diseases, with favorable results in the short and medium term, allowing the restoration of ventricular function with minimal risk, compared to surgical replacement in selected patients.
Subject(s)
Humans , Male , Adolescent , Pulmonary Valve Insufficiency/surgery , Pulmonary Valve Stenosis/surgery , Heart Valve Prosthesis Implantation/methods , Prosthesis Design , Pulmonary Valve/surgery , Pulmonary Valve/pathology , Pulmonary Valve Insufficiency/congenital , Pulmonary Valve Stenosis/congenital , ColombiaABSTRACT
Abstract Background and objectives: The aneurysm in the pulmonary trunk is a rare disease. Because of its location, a rupture can lead to right ventricular failure and sudden death. Aneurysmorraphy is the most widely used surgical treatment in these cases. The aim of this study is to report a successful balanced general anesthesia for aneurysmorraphy of pulmonary trunk. Case report: Male patient, 28 years, asymptomatic, diagnosed with an aneurysm in the pulmonary trunk. According to the location of the aneurysm and the consequent failure of the pulmonary valve, an aneurysmorraphy was indicated, with implantation of vascular-valvular prosthesis (valved tube). We opted for a balanced general anesthesia, seeking to prevent an increase in systemic and pulmonary vascular resistances, thus avoiding to cause stress on the wall of the aneurysmal vessel. Conclusions: A balanced general anesthesia, in combination with adequate ventilation to prevent elevation in pulmonary vascular pressure, was appropriate for surgical repair of an aneurysm in the pulmonary trunk.
Resumo Justificativa e objetivos: O aneurisma de tronco de artéria pulmonar é uma doença rara. Por sua localização, uma ruptura pode conduzir à falência do ventrículo direito e à morte súbita. A aneurismorrafia é o tratamento cirúrgico mais usado nesses casos. O objetivo foi relatar uma anestesia geral balanceada para aneurismorrafia de tronco de artéria pulmonar feita com sucesso. Relato do caso: Paciente do sexo masculino, 28 anos, assintomático, diagnosticado com aneurisma de tronco de artéria pulmonar. De acordo com a localização do aneurisma e a consequente insuficiência da válvula pulmonar, foi indicada a aneurismorrafia com implante de prótese vascular e valvular (tubo valvado). Optou-se pela anestesia geral balanceada, para impedir um aumento nas resistências vasculares sistêmicas e pulmonar e evitar-se, dessa maneira, um estresse sobre a parede do vaso aneurismático. Conclusões: A anestesia geral balanceada, em associação com uma ventilação adequada para evitar elevação na pressão vascular pulmonar, foi apropriada para correção cirúrgica de um aneurisma em tronco pulmonar.
Subject(s)
Humans , Male , Adult , Pulmonary Artery/surgery , Pulmonary Valve/surgery , Aneurysm/surgery , Pulmonary Artery/drug effects , Heart Valve Prosthesis , Radiography , Heart Valve Prosthesis Implantation/methods , Aneurysm/diagnostic imagingSubject(s)
Humans , Female , Infant , Pulmonary Valve/abnormalities , Pulmonary Valve/surgery , Bronchi/surgery , Stents , SyndromeABSTRACT
A cardiopatia reumática é um importante problema de saúde pública. Há escassez de dados sobreinfluência de variáveis cirúrgicas na mortalidade de pacientes reumáticos submetidos dupla-troca valvar (DTV).Objetivo: Identificar possíveis variáveis cirúrgicas associadas à mortalidade de pacientes reumáticos submetidos à DTV.Métodos: Estudo retrospectivo de corte transversal, incluindo 104 pacientes >18 anos, com diagnóstico prévio devalvopatia reumática, submetidos à cirurgia de DTV no período de janeiro de 2007 a dezembro de 2011. A coletade dados utilizou os prontuários de pacientes do Hospital Ana Nery, Salvador, BA, Brasil.Resultados: Observou-se diferença estatística significativa entre os grupos do desfecho (óbito intra-hospitalar/alta hospitalar) em relação às variáveis, respectivamente: tempo de anoxia (minutos) de 149,17±40,99 e 123,99±24,12(p=0,001); tempo de CEC 185,53±54,59 e 157,34±34,62 (p=0,006); e o tempo cirúrgico total 350,29±56,69 e 295,23±63,98(p=0,002). Os pacientes que realizaram outro procedimento associado à DTV, no mesmo tempo cirúrgico,apresentaram maior mortalidade (n=10; 31,2%), em relação aos que realizaram apenas a DTV (n=9; 12,8%) (p=0,027).Houve também associação significativa na comparação de pacientes com reabordagem cirúrgica com aqueles querealizaram única abordagem (p<0,001). Não houve diferença estatística quando se comparou desfecho hospitalare os tipos de próteses utilizadas (p=0,219). Conclusões: As variáveis cirúrgicas que tiveram influência na mortalidade foram: tempos de anoxia, de CEC, de cirurgia total, com possíveis pontos de corte, respectivamente, de 150 min, 100 min e 300 min. A necessidade de reabordagemno pós-operatório hospitalar e a realização de outro procedimento no mesmo ato também mostraram significância...
Rheumatic heart disease is a major public health issue. Data on the influence of surgical variables in mortality in rheumatic patients undergoing double valve replacement (DVR) are scarce. Objective: Identify potential surgical variables associated with mortality in rheumatic patients undergoing DVR. Methods: Retrospective cross-sectional study including 104 patients over 18 years, previously diagnosed with rheumatic heart-valve disease, and undergoing DVR surgery from January 2007 to December 2011. Data collection: medical records of patients from HospitalAna Nery, Salvador, Brazil.Results: Outcome groups (in-hospital death vs. hospital discharge) had a significant statistical difference in relation to variables, respectively:anoxia time (in minutes) of 149.17±40.99 and 123.99±24.12 (p=0.001); CPB time 185.53±54.59 and 157.34±34.62 (p=0.006); and totalsurgical time 350.29±56.69 and 295.23±63.98 (p=0,002). Patients who underwent another procedure associated with DVR for the same surgical time showed higher mortality rates (n=10; 31.2%) compared to those who underwent DVR only (n=9, 12.8%) (p=0.027). There was also a significant association when comparing patients with surgical rapprochement with those who underwent one surgery only(p<0.001). There was no statistical difference between hospital outcome and the types of prostheses used (p=0.219). Conclusions: The surgical variables that influenced mortality were: anoxia, CPB and total surgical times, with potential cutoff points of 150, 100 and 300 minutes, respectively. The need for rapprochement during the in-hospital postoperative period, and the performance of another associated procedure in the same surgery were also significant...
Subject(s)
Humans , Male , Female , Middle Aged , Rheumatic Heart Disease/complications , Rheumatic Heart Disease/diagnosis , Heart Valve Diseases/complications , Hospital Mortality , Aortic Valve/surgery , Mitral Valve/surgery , Pulmonary Valve/surgery , Brazil , Extracorporeal Circulation/methods , Prevalence , Prostheses and Implants , Retrospective Studies , Rheumatic Fever , Risk Factors , Data Interpretation, StatisticalABSTRACT
Carcinoid is a rare neuroendocrine tumor typically arising in the gastrointestinal tract that can cause heart valve involvement. We report two patients with carcinoid syndrome and tricuspid/pulmonary valve lesions. A 33-year-old male presenting with fatigue and weight loss: A tumor in the tail of the pancreas was found on an abdominal CAT scan. The percutaneous biopsy was informed as a carcinoid tumor. A trans-esophageal echocardiogram showed a tricuspid and pulmonary valve involvement, which was replaced surgically. The biopsy informed an extensive fibrous and myxoid degeneration of the valves. A 35-year-old male with a carcinoid syndrome and cardiac failure: An echocardiogram showed a severe tricuspid stenosis and severe pulmonary regurgitation. The patient was subjected to a double surgical valve replacement. The pathology report of the excised valve showed a deforming fibrous and myxoid valvulopathy.
Subject(s)
Adult , Humans , Male , Carcinoid Heart Disease/diagnosis , Heart Valve Diseases/diagnosis , Pulmonary Valve , Tricuspid Valve , Carcinoid Heart Disease/surgery , Heart Valve Diseases/surgery , Pulmonary Valve/surgery , Tricuspid Valve/surgeryABSTRACT
A correção cirúrgica de algumas cardiopatias congênitas complexas envolve a reconstrução da via de saída do ventrículo direito com a interposição de homoenxertos, biopróteses, enxertos de jugular bovina ou outros condutos valvulados entre o ventrículo direito e o tronco da artéria pulmonar. Apesar de essas cirurgias poderem ser realizadas com baixa mortalidade, a vida útil das válvulas ou dos condutos implantados é normalmente pequena (< 10 anos), seja por degeneração e/ou calcificação. Graus variáveis de estenose pulmonar na maioria das vezes associada a insuficiência pulmonar são consequências da degeneração dos condutos. Em 2000, Bonhoeffer et al. foram os primeiros a relatar o implante transcateter de bioprótese valvular pulmonar (ITVP) com um dispositivo que posteriormente foi denominado de válvula Melody® (Medtronic, Minneapolis, Estados Unidos). A técnica foi inicialmente desenvolvida para limitar a necessidade de múltiplos procedimentos cirúrgicos, substituindo, em última análise, uma nova troca cirúrgica valvular. Estudos subsequentes na Europa e Estados Unidos atestaram para a segurança e eficácia dessa técnica em um número maior de pacientes. Como a Agência Nacional de Vigilância Sanitária (Anvisa) concedeu a aprovação para o uso clínico da válvula biológica pulmonar transcateter Melody® em fevereiro de 2013, consideramos necessária e oportuna a avaliação judiciosa da utilização dessa nova tecnologia antes que ela fosse aplicada em larga escala em nosso país. O objetivo deste estudo foi realizar uma revisão sistemática da literatura sobre o ITVP em pacientes com disfunções de homoenxertos, condutos valvulados e biopróteses implantados cirurgicamente na via de saída do ventrículo direito.
Surgical repair of some complex congenital heart diseases involves reconstruction of the right ventricular outflow tract using homografts, bioprostheses, bovine jugular grafts or other valved conduits between the right ventricle and the main pulmonary artery. Although these surgical procedures may be performed with low mortality rates, the life span of these implanted valves or conduits is usually short (< 10 years) due to either degeneration and/or calcification. Variable degrees of pulmonary stenosis, often associated with pulmonary insufficiency, are consequences of conduit degeneration. In 2000, Bonhoeffer et al. were the first to report the transcatheter pulmonary valve implantation (TPVI) of a bioprosthetic pulmonary valve later named Melody® valve (Medtronic, Minneapolis, USA). The technique was initially developed to limit the need for multiple surgical procedures, and, ultimately, to work as a surrogate of a new surgical valve replacement. Subsequent clinical studies in Europe and the United States confirmed the safety and efficacy of this technique in a larger number of patients. Since the National Sanitary Surveillance Agency (Agência Nacional de Vigilância Sanitária - Anvisa) granted approval for clinical use of the Melody® transcatheter pulmonary biological valve in February 2103, we deemed that a judicious assessment of this new technology was timely and necessary before the widespread use in our country. The objective of this study was to perform a systematic literature review on the use of TPVI in patients with dysfunctional homografts, valved conduits and bioprostheses implanted surgically in the right ventricular outflow tract.
Subject(s)
Humans , Cardiac Catheterization/methods , Prostheses and Implants , Heart Valve Prosthesis , Pulmonary Valve/surgery , Heart Defects, Congenital/surgery , Review Literature as TopicSubject(s)
Humans , Male , Middle Aged , Bioprosthesis , Carcinoid Heart Disease/complications , Pulmonary Valve/surgery , Tricuspid Valve/surgery , Pulmonary Valve Insufficiency/etiology , Pulmonary Valve Insufficiency/surgery , Tricuspid Valve Insufficiency/etiology , Tricuspid Valve Insufficiency/surgeryABSTRACT
INTRODUÇÃO: As biopróteses valvares cardíacas estão relacionadas a eventos tromboembólicos, infecciosos e degenerativos. Seu desgaste é atribuído principalmente à desnaturação do colágeno. O glutaraldeído, método predominante de preservação de biopróteses, favorece o processo de calcificação e limita sua durabilidade. Diversas técnicas tentam conter o processo degenerativo das biopróteses. OBJETIVO: Avaliar o processo de calcificação, in vivo, de heteroenxertos pulmonares valvados, preservados em meio não-aldeídico (L-Hydro®). MÉTODOS: Dezessete carneiros foram submetidos à substituição do tronco da artéria pulmonar por enxerto tubular valvado de pericárdio bovino. Os animais foram distribuídos em dois grupos: Grupo L-Hydro® (teste / n=14) e Grupo Glutaraldeído (controle /n=3). Cerca de 150 dias pós-implante os animais foram sacrificados, necropsiados e as próteses submetidas a estudo anatomopatológico, avaliação radiológica e dosagem do cálcio por espectrofotometria de absorção atômica. A análise estatística foi obtida por meio dos testes exato de Fisher, T de Student ou Mann-Whitney (significância: 5%). RESULTADOS: A avaliação radiológica, macroscopia, microscopia e dosagem de cálcio por espectrofotometria de absorção atômica demonstraram maior calcificação nas próteses do Grupo Glutaraldeído, quando comparadas às próteses do Grupo L-Hydro® (P=0,001). Sete animais do Grupo L-Hydro® (50%) apresentaram aderência das cúspides à parede do tubo (P=0,228). CONCLUSÕES: As próteses preservadas em L-Hydro® demonstraram-se mais resistentes à calcificação, quando comparadas às preservadas em glutaraldeído.
INTRODUCTION: The cardiac bioprostheses are related to thromboembolic events, infectious and degenerative diseases. Wear is mainly attributed to the denaturation of collagen. Glutaraldehyde, the predominant method of preservation of bioprostheses, favors the calcification process and limits their durability. Several techniques try to contain the degenerative process of bioprostheses. OBJECTIVES: To evaluate the process of calcification in vivo pulmonary valve heterografts preserved in non-aldehydic (L-Hydro®). METHODS: Seventeen sheep underwent replacement of the pulmonary artery valved tubular grafts of bovine pericardium. The animals were divided into two groups: Group L-Hydro® (test / n = 14) and Group Glutaraldehyde (control / n = 3). About 150 days after implantation the animals were sacrificed, necropsied and implants subjected to a pathological study, radiological evaluation and measurement of calcium by atomic absorption spectrophotometry. Statistical analysis was obtained through the Fisher's exact test, Student's t or Mann-Whitney test (significance: 5%). RESULTS: The radiological evaluation, the macroscopic and microscopic measurement of serum calcium by atomic absorption spectrophotometry showed increased calcification of the prosthetic group Glutaraldehyde, when compared to denture-HydroR Group L (P = 0.001). Seven animals in Group L-Hydro® (50%) had adherence of the leaflets to the wall of the tube (P = 0.228). CONCLUSIONS: Prostheses preserved in L-Hydro® were more resistant to calcification when compared with glutaraldehyde preserved.
Subject(s)
Animals , Bioprosthesis , Calcinosis/physiopathology , Glutaral , Heart Valve Prosthesis , Heart Valve Prosthesis Implantation/methods , Pulmonary Artery/surgery , Pulmonary Valve/surgery , Calcinosis/pathology , Calcium/blood , Prosthesis Design , Prosthesis Failure , Pulmonary Artery/pathology , Pulmonary Artery , Sheep , Spectrophotometry, Atomic , Time FactorsABSTRACT
Relatamos a seguir um caso clínico de endocardite isolada de valva pulmonar em um paciente sem fatores de risco clássicos para essa patologia.
Subject(s)
Humans , Male , Adult , Echocardiography, Transesophageal/methods , Echocardiography, Transesophageal , Endocarditis/complications , Endocarditis/diagnosis , Pulmonary Valve/surgery , Risk FactorsSubject(s)
Cardiac Surgical Procedures , Cardiomegaly/etiology , Cardiomegaly/surgery , Child, Preschool , Echocardiography , Heart Atria/surgery , Humans , Intraoperative Care/methods , Male , Pulmonary Atresia/diagnostic imaging , Pulmonary Atresia/therapy , Pulmonary Atresia/diagnostic imaging , Pulmonary Valve/surgery , Radiography, Thoracic , Tricuspid Valve/surgery , Ventricular Septum/physiology , Ventricular Septum/diagnostic imaging , Ventricular Septum/diagnostic imagingABSTRACT
OBJETIVO: Avaliar o processo de descelularização com dodecil sulfato de sódio (SDS) como método anticalcificante em próteses de pericárdio bovino fixadas em glutaraldeído, em modelo circulatório de ovinos. MÉTODOS: Tubos valvulados de pericárdio bovino foram implantados em posição pulmonar de ovinos por 180 dias. Os animais foram divididos em dois grupos com oito animais: grupo controle, com condutos de pericárdio fixado em glutaraldeído e grupo estudo, com pericárdio descelularizado com SDS 0,1% e posteriormente fixado em GDA. Os explantes foram submetidos à análise macroscópica, histológica com hematoxilina-eosina, alizarina-red e pentacrômico de Russel-Movatz, estudo radiológico e quantificação de cálcio com espectrometria de absorção atômica. RESULTADOS: Não houve mortalidade imediata, porém dois animais de cada grupo faleceram na evolução tardia. Os enxertos do grupo controle apresentavam intensa calcificação das cúspides e em algumas regiões dos condutos, enquanto que os enxertos descelularizados apresentavam-se preservados, sem calcificações macroscópicas evidentes. Esses resultados foram comprovados por análise histológica e radiográfica. Histologicamente, os enxertos descelularizados tiveram sua matriz melhor preservada e com diminuição acentuada da calcificação. O conteúdo de cálcio nos condutos foi de 35±42 µg/mg de tecido no grupo controle versus 15 ±10 µg/mg nos descelularizados. Nas cúspides valvares, esses valores foram de 264±126 µg/mg no grupo controle versus 94±27 µg/mg nos descelularizados (P=0,009). CONCLUSÃO: A descelularização com SDS 0,1% foi efetiva como método anticalcificante em condutos de pericárdio bovino implantados em modelo circulatório de ovinos por 180 dias.
OBJECTIVE: The objective was to analyze the decellularization process with SDS in glutaraldehyde-preserved bovine pericardium as an anticalcification method in a circulatory sheep model. METHODS: The valved tubs were implanted in pulmonary artery position in sheep by 180 days. The animals were divided in two groups of 8 animals: control group glutaraldehyde-preserved bovine pericardium and the study group - decellularized bovine pericardium with 0,1% SDS and glutaraldehyde-preserved. After explantation the tubs were analized by x-ray macroscopy, hematoxilin-eosin, alizarin-red and Russel-Movatz pentacromic histology. The calcium content was measured by flame atomic absorption spectrometry. RESULTS: There was no early mortality, but two animals in each group died during the study. All cusps in the control group were severely calcified and in some points in the conduits, while the decellularized group did not show macroscopic calcification. Data were proved by x-ray and histologycal exams. The matrix was preserved in histologycal analysis in decellularized group, without gross calcification. The wall conduits calcium content was 35,25±42,13 µg/mg in the control group versus 15,75±10,44 µg/mg in the decellularized one: in the cusps was 264,4±126,16 µg/mg in control group versus 94,29±27,05 µg/mg in decellularized group (P=0,009). CONCLUSION: The decellularization with 0.1% SDS was effective as an anticalcification method in bovine pericardial grafts implanted in a sheep circulatory model for 180 days.
Subject(s)
Animals , Bioprosthesis/adverse effects , Calcinosis/prevention & control , Heart Valve Prosthesis/adverse effects , Pulmonary Valve/surgery , Tissue Engineering/methods , Calcium/analysis , Models, Animal , Pulmonary Valve/pathology , Pulmonary Valve , Random Allocation , Sheep , Statistics, Nonparametric , Sodium Dodecyl Sulfate/chemistryABSTRACT
Congenital heart diseases are a major part of Costello and cardio-facio-cutaneous syndromes. Subaortic stenosis was reported rarely and Ross operation never in these syndromes. We reported a girl patient whose manifestations were consistent with these syndromes. Distinction between these syndromes was not possible as genetic testing was not carried out. She developed severe neoaortic regurgitation 2.5 years after the Ross operation and died due to the complications of aortic valve replacement. Ross operation may be an unsuitable option in these syndromes due to the possibility of subtle pulmonic valve pathology.
Subject(s)
Cardiac Surgical Procedures/adverse effects , Costello Syndrome/surgery , Costello Syndrome/mortality , Costello Syndrome/therapy , Child , Discrete Subaortic Stenosis/mortality , Female , Humans , Neurocutaneous Syndromes/mortality , Neurocutaneous Syndromes/surgery , Neurocutaneous Syndromes/therapy , Pulmonary Valve/surgeryABSTRACT
FUNDAMENTO: O homoenxerto pulmonar tem sido utilizado como uma opção na correção de cardiopatia congênita com obstrução da via de saída do ventrículo direito. Os resultados em longo prazo, no entanto, mostram-se pouco satisfatórios. OBJETIVO: Identificar os fatores de risco associados à disfunção e à falência do homoenxerto pulmonar. MÉTODOS: Estudo em crianças submetidas à ampliação da via de saída do ventrículo direito com homoenxerto pulmonar. As variáveis clínicas, cirúrgicas, evolutivas e de aspectos morfológicos da prótese foram analisadas como fatores de risco. RESULTADOS: A amostra final de 75 pacientes com idade mediana na cirurgia de 22 meses, variando de 1-157 meses, apresentou 13 pacientes (17,0 por cento) que desenvolveram disfunção do homoenxerto, caracterizado por estenose ou insuficiência pulmonar grave. O tempo de ocorrência entre o implante do homoenxerto e a detecção da disfunção foi de 45 ± 20 meses. Quando o tamanho do homoenxerto foi menor de 21 mm e o escore Z da valva pulmonar foi menor do que zero, ou maior do que três, foram considerados fatores de risco para a ocorrência de disfunção. CONCLUSÃO: O homoenxerto pulmonar de tamanho menor do que 21 mm e a valva pulmonar inadequada para idade e peso do paciente são fatores determinantes para disfunção da prótese.
BACKGROUND: The pulmonary homograft has been used as an option in the correction of congenital cardiopathy with obstruction of the right ventricle exit tract. The long term results, however, are little satisfactory. OBJECTIVE: Identify the risk factors associated to the dysfunction and the pulmonary homograft failure. METHODS: Study with children submitted to the enlargement of the exit tract of the right ventricle with pulmonary homograft. The clinical, surgical, evolutional and morphological aspects of the prosthesis variables were analyzed as risk factors. RESULTS: The final sample of 75 patients with median age at the surgery of 22 months, varying from 1-157 months, presented 13 patients (17.0 percent) who developed dysfunction of the homograft, characterized by stenosis or severe pulmonary insufficiency. The occurrence time between the homograft implant and the detection of the dysfunction was of 45 ± 20 months. When the size of the homograft was smaller than 21 mm and the Z score of the pulmonary valva is lower than zero, or higher than three, the risk factors were considered for the dysfunction occurrence. CONCLUSION: The pulmonary homograft smaller than 21 mm and the inadequate pulmonary valva for the age and weight of the patient are determining factors for the prosthesis dysfunction.
FUNDAMENTO: El homoinjerto pulmonar ha sido utilizado como una opción en la corrección de cardiopatía congénita con obstrucción de la vía de salida del ventrículo derecho. Los resultados a largo plazo, mientras tanto, se muestran poco satisfactorios. OBJETIVO: Identificar los factores de riesgo asociados a la disfunción y a la falla del homoinjerto pulmonar. MÉTODOS: Estudio en niños sometidos a la ampliación de la vía de salida del ventrículo derecho con homoinjerto pulmonar. Las variables clínicas, quirúrgicas, evolutivas y de aspectos morfológicos de la prótesis fueron analizadas como factores de riesgo. RESULTADOS: La muestra final de 75 pacientes con edad mediana en la cirugía de 22 meses, variando de 1-157 meses, presentó 13 pacientes (17,0 por ciento) que desarrollaron disfunción del homoinjerto, caracterizado por estenosis o insuficiencia pulmonar grave. El tiempo de ocurrencia entre el implante del homoinjerto y la detección de la disfunción fue de 45 ± 20 meses. Cuando el tamaño del homoinjerto fue menor de 21 mm y el escore Z de la válvula pulmonar fue menor que cero, o mayor que tres, fueron considerados factores de riesgo para la ocurrencia de disfunción. CONCLUSIÓN: El homoinjerto pulmonar de tamaño menor que 21 mm y la válvula pulmonar inadecuada para edad y peso del paciente son factores determinantes para disfunción de la prótesis.